How Do Out-of-Pocket Expenditures Affect Healthcare: A Qualitative Insight of Acute Exacerbation among Asthma Patients

Introduction: This study was designed todetermine the out of pocket costs (OOPCs) of acute exacerbation of asthma (AEA) in asthma patients attending a public hospital.Methodology:A cross-sectionalstudy was done by interviewing the patients using the convenience sampling technique. Data were obtained based on per episode of AEA. OOPCs were calculated based on direct and indirect costs. A total of 128patients participated in the study. The data were analyzed with SPSS ver 23.Results: The study group comprised of 88 males (68.8%), 57 (44.5%) singles and 67 (52.3%) less than 40 years of age. There were considerable differences found between the severity levels and lengths of hospital stay towards theOOPCs. Conclusion:The severity of the AEA and length of stay in the hospital increase the per episode OOPCs of AEA among asthma patients

Pharmacoeconomic Analysis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Introduction:Chronic obstructive pulmonary disease (COPD) imparts a substantial economic burden on an individual and society. Exacerbation of COPD (ECOPD) is the primary cost driver for this burden as it usually associated with hospital admissions of COPD patients. The present study aimed to determine the direct costs of acute ECOPD among COPD patients.Methods:A total of 90 eligible patients with acute ECOPD who were admitted to the hospital were involved in this study. A convenient sampling technique was used during data collection. Cost data were collected according to the expenditures and existing information. Data were analyzed using Statistical Package for the Social Sciences (SPSS) version 23.0. TheSpearman's rank test was used to observe the differences (correlations) between the Govt perspective and the patient perspective.Results:The direct costs per episode of acute ECOPD were determined according to the Anthonisen criteria for evaluating acute ECOPD. The mean direct costs for severity III, severity I and severity I were 89.1, 134.8 and 178.2 USD respectively. The cost of acute ECOPD was positively associated with disease severity, length of hospital stay and the number of co-morbidities.Conclusion:Acute ECOPD patients consume a considerable amount of healthcare resources and pose a significant economic burden on the government

External ophthalmomyiasis a case report

Ophthalmomyiasis is an infestation of the eye with larvae of most common sheep nasal botfly [Oestrus ovis] We describe a case of ophthalmomyiasis in a 50-year-old man who presented with ocular foreign body sensation, redness and tearing. The causative larvae were removed in the emergency room and sent to laboratory for identification. The patient symptoms improved after topical treatment with antibiotics-steroid combination therapy

gene therapy revolution in ophthalmology

The advances in gene therapy hold significant promise for the treatment of ophthalmic conditions. Several studies using animal models have been published. Animal models on retinitis pigmentosa, Leber's Congenital Amaurosis [LCA], and Stargardt disease have involved the use of adeno-associated virus [AAV] to deliver functional genes into mice and canines. Mice models have been used to show that a mutation in cGMP phosphodiesterase that results in retinitis pigmentosa can be corrected using rAAV vectors. Additionally, rAAV vectors have been successfully used to deliver ribozyme into mice with a subsequent improvement in autosomal dominant retinitis pigmentosa. By using dog models, researchers have made progress in studying X-linked retinitis pigmentosa which results from a RPGR gene mutation. Mouse and canine models have also been used in the study of LCA. The widely studied form of LCA is LCA2, resulting from a mutation in the gene RPE65. Mice and canines that were injected with normal copies of RPE65 gene showed signs such as improved retinal pigment epithelium transduction, visual acuity, and functional recovery. Studies on Stargardt disease have shown that mutations in the ABCA4 gene can be corrected with AAV vectors, or nanoparticles. Gene therapy for the treatment of red-green color blindness was successful in squirrel monkeys. Plans are at an advanced stage to begin clinical trials. Researchers have also proved that CD[59] can be used with AMD. Gene therapy is also able to treat primary open angle glaucoma [POAG] in animal models, and studies show it is economically viable